Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection
NCT02932150Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Nov 2016; status: active, not recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02932150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932150.